Tonghua Jinma announced that on August 6, 2026, Guilin Jinma, a wholly-owned subsidiary of the company, signed a “M&A Intent Agreement” with Eight Plus One Pharmaceutical to acquire its controlling interest. Eight Plus One Pharmaceuticals has 23 drug development patents and 3 clinical approvals for Class 1 new drugs. The due diligence period is 60 days, and the exclusive period is 90 days. The transaction consideration is subject to negotiation, and subsequent decision-making and approval procedures must be carried out. The target company has unresolved execution cases, there is uncertainty about the listing of products under development, and there are many uncertainties about this merger and acquisition.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.